Search

Your search keyword '"KISH, JONATHAN"' showing total 29 results
Start Over Author "KISH, JONATHAN" Publication Year Range Last 3 years
29 results on '"KISH, JONATHAN"'

6. Real-World Use of Fedratinib for Myelofibrosis Following Prior Ruxolitinib Failure: Patient Characteristics, Treatment Patterns, and Clinical Outcomes

Author

Mascarenhas, John, primary, Harrison, Claire, additional, Schuler, Tammy A., additional, Liassou, Djibril, additional, Garretson, Marné, additional, Miller, Taavy A., additional, Mahadevan, Sankar, additional, McBride, Ali, additional, Tang, Derek, additional, DeGutis, Irene S., additional, Abraham, Pranav, additional, Kish, Jonathan, additional, Feinberg, Bruce A., additional, and Gerds, Aaron T., additional

Published
2023
Full Text
View/download PDF

7. Characteristics, Treatment, and Outcomes of Real-World Talazoparib-Treated Patients With Germline BRCA-Mutated Advanced HER2-Negative Breast Cancer

Author

Zimmerman Savill, Kristin M, primary, Ivanova, Jasmina, additional, Asgarisabet, Parisa, additional, Falkenstein, Angelica, additional, Balanean, Alexandrina, additional, Niyazov, Alexander, additional, Ryan, Joanne C, additional, Kish, Jonathan, additional, Gajra, Ajeet, additional, and Mahtani, Reshma L, additional

Published
2023
Full Text
View/download PDF

12. Better Together? Costs of First-line Chemoimmunotherapy for Advanced Non-Small Cell Lung Cancer.

Author

Kish, Jonathan, Liassou, Djibril, Hartman, John, Lubinga, Solomon J., Chopra, Dhruv, and Feinberg, Bruce

Subjects
*THERAPEUTIC use of antineoplastic agents, *LUNG cancer, *CONFIDENCE intervals, *CANCER chemotherapy, *ANTINEOPLASTIC agents, *MEDICAL care costs, *RETROSPECTIVE studies, *MEDICAL care use, *DESCRIPTIVE statistics, *RESEARCH funding, *IMMUNOTHERAPY
Abstract

OBJECTIVES: Recent advances have created options for first-line (1L) treatment of advanced/metastatic non--small cell lung cancer (aNSCLC). The study objectives were to describe the utilization of 3 classes of 1L treatment--chemotherapy (CT), immunotherapy (IO), and chemoimmunotherapy (IO+CT)--and the total, third-party payer, direct health care costs. STUDY DESIGN: Retrospective, administrative claims database analysis of patients with aNSCLC who initiated 1L treatment between January 1, 2017, and May 31, 2019, with IO, CT, or IO+CT. METHODS: Microcosting enumerated health care resource utilization, including antineoplastic drug costs, using standardized costs. Generalized linear models estimated per-patient per-month (PPPM) costs during 1L treatment, and adjusted cost differences in 1L among treatment cohorts were calculated using recycled predictions. RESULTS: A total of 1317 IO-, 5315 CT-, and 1522 IO+CTtreated patients were identified. Utilization of CT declined from 72.3% to 47.6% between 2017 and 2019, replaced by use of IO+CT, which increased from 1.8% to 29.8%. Total PPPM costs in 1L were highest with IO+CT at $32,436, compared with $19,000 and $17,763 in the CT and IO cohorts, respectively. Adjusted analyses showed that PPPM costs were $13,933 (95% CI, $11,760-$16,105) higher in the IO+CT vs IO cohort (P < .001) and IO costs were $1024 (95% CI, $67-$1980) lower than CT (P = .04). CONCLUSIONS: IO+CT accounts for almost one-third of 1L aNSCLC treatment modalities, coinciding with a reduction in treatment with CT. Costs for patients treated with IO were lower than those for patients treated with both IO+CT and CT alone, driven primarily by antineoplastic drug and associated medical costs. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

13. Characteristics, Treatment, and Outcomes of Real-World Talazoparib-Treated Patients With Germline BRCA-Mutated Advanced HER2-Negative Breast Cancer.

Author

Savill, Kristin M Zimmerman, Ivanova, Jasmina, Asgarisabet, Parisa, Falkenstein, Angelica, Balanean, Alexandrina, Niyazov, Alexander, Ryan, Joanne C, Kish, Jonathan, Gajra, Ajeet, and Mahtani, Reshma L

Subjects
THERAPEUTIC use of antineoplastic agents, GENETIC mutation, CONFIDENCE intervals, BRCA genes, CANCER chemotherapy, METASTASIS, RETROSPECTIVE studies, ACQUISITION of data, TREATMENT effectiveness, BRAIN tumors, TREATMENT failure, CANCER patients, MEDICAL records, DESCRIPTIVE statistics, SURVIVAL analysis (Biometry), RESEARCH funding, PROGRESSION-free survival, BREAST tumors, ENZYME inhibitors, EVALUATION, ADULTS
Abstract

Background Talazoparib is a poly (adenosine diphosphate-ribose) polymerase inhibitor approved for the treatment of adult patients with deleterious or suspected deleterious germline BRCA -mutated (g BRCA m), HER2-negative, locally advanced or metastatic breast cancer (LA/mBC), with approval based on the EMBRACA trial. To date, there are no published data on talazoparib use in the real-world United States (USA) setting. Patients and Methods Characteristics, treatment patterns, and clinical outcomes of real-world US patients with g BRCA m HER2-negative LA/mBC treated with talazoparib monotherapy were collected via retrospective chart review and summarized using descriptive statistics. Results Among 84 eligible patients, 35.7% had hormone receptor-positive tumors and 64.3% had triple-negative LA/mBC (TNBC). At talazoparib initiation, 29.8% had ECOG PS of ≥2 and 19.0% had brain metastasis. Mutations in g BRCA1 or 2 were detected among 64.3% and 35.7% of patients, respectively. Talazoparib was given as 1st-line therapy in 14.3% of patients, 2nd-line in 40.5%, and 3rd- or 4th-line in 45.2%. Median time to talazoparib treatment failure was 8.5 months (95% CI, 8.0-9.7), median progression-free survival was 8.7 months (95% CI, 8.0-9.9), the median time from initiation to chemotherapy was 12.2 months (95% CI, 10.5-20.1), and the overall response rate was 63.1%. No differences in clinical outcomes were observed between patients with HR-positive/HER2-negative LA/mBC and patients with TNBC by using unadjusted statistical comparisons. Brain metastasis and ECOG PS ≥2 at talazoparib initiation were associated with treatment failure and progression or mortality. Conclusion Overall, talazoparib clinical outcomes in this real-world population are consistent with findings from EMBRACA. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

15. Real-world erythropoiesis-stimulating agent (ESA) treatment patterns and outcomes among U.S. patients with lower-risk myelodysplastic syndromes (LR-MDS).

Author

Mukherjee, Sudipto, primary, Savill, Kristin M. Zimmerman, additional, Gajra, Ajeet, additional, Kish, Jonathan K., additional, Brown-Bickerstaff, Cherrishe, additional, Gentile, Danielle, additional, Falkenstein, Angelica, additional, Miller, Talia, additional, Laney, Jalyna R., additional, and McBride, Ali, additional

Published
2022
Full Text
View/download PDF

18. Economic and clinical impact of a novel, light-based, at-home antiviral treatment on mild-to-moderate COVID-19

Author

Gibson, Scott, Saunders, Rhodri, Stasko, Nathan, Bickerstaff, Cherrishe-Brown, Oakley, John, Osterman, Mark, Torres, Rafael Torrejon, Kish, Jonathan K., Feinberg, Bruce A., and Emerson, David

Subjects
Health Policy, Cost-Benefit Analysis, Vaccination, COVID-19, Humans, Health Care Costs, Antiviral Agents
Abstract

Antiviral treatments for early intervention in patients with mild-to-moderate COVID-19 are needed as a complement to vaccination. We sought to estimate the impact on COVID-19 cases, deaths, and direct healthcare costs over 12 months following introduction of a novel, antiviral treatment, RD-X19, a light-based, at-home intervention designed for the treatment of mild-to-moderate COVID-19 infection. A time-dependent, state transition (semi-Markov) cohort model was developed to simulate infection progression in individuals with COVID-19 in 3 US states with varying levels of vaccine uptake (Alabama, North Carolina, and Massachusetts) and at the national level between 1 June 2020 and 31 May 2021. The hypothetical cohort of patients entering the model progressed through subsequent health states after infection. Costs were assigned to each health state. Number of infections/vaccinations per day were incorporated into the model. Simulations were run to estimate outcomes (cases by severity, deaths, and direct healthcare costs) at various levels of adoption of RD-X19 (5%, 10%, 25%) in eligible infected individuals at the state and national levels and across three levels of clinical benefit based on the results from an early feasibility study of RD-X19. The clinical benefit reflects a decline in the duration of symptomatic disease by 1.2, 2.4 (base case), and 3.6 days. In the base case analysis with 10% adoption, simulated infections/deaths/direct healthcare costs were reduced by 10,059/275/$69 million in Alabama, 21,092/545/$135 million in North Carolina, and 16,670/415/$102 million in Massachusetts over 12 months. At the national level, 10% adoption reduced total infections/deaths/direct healthcare costs by 686,722/17,748/$4.41 billion. At-home, antiviral treatment with RD-X19 or other interventions with similar efficacy that decrease both symptomatic days and transmission probabilities can be used in concert with vaccines to reduce COVID-19 cases, deaths, and direct healthcare costs.

Published
2022
Full Text
View/download PDF

24. Clinical Outcomes at 3 and 6 Months of Fedratinib Therapy Following Prior Ruxolitinib Failure: Real-World Assessment of Spleen, Symptoms, and Hematologic Response

Author

Mascarenhas, John, primary, Gerds, Aaron T., additional, Kee, Arianna, additional, Kish, Jonathan K., additional, Abraham, Pranav, additional, Balanean, Alexandrina, additional, Nadal, Jose Alberto, additional, Liassou, Djibril, additional, Feinberg, Bruce A., additional, McBride, Ali, additional, and Harrison, Claire N., additional

Published
2021
Full Text
View/download PDF

25. Real-World Utilization of Fedratinib for Myelofibrosis Post-Ruxolitinib: Patient Characteristics, Treatment Patterns, and Characterization of Ruxolitinib Failure

Author

Harrison, Claire N., primary, Mascarenhas, John, additional, Abraham, Pranav, additional, Kee, Arianna, additional, Nadal, Jose Alberto, additional, Balanean, Alexandrina, additional, McBride, Ali, additional, Kish, Jonathan K., additional, Liassou, Djibril, additional, Feinberg, Bruce A., additional, and Gerds, Aaron T., additional

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results